Análisis de subpoblaciones monocitarias en relación con los factores de riesgo cardiovascular

  1. Marcos Jubilar, María 1
  2. Orbe, Josune
  3. Roncal, Carmen
  4. Fernández Montero, Alejandro 1
  5. Colina, Inmaculada 1
  6. Rodil, Raquel 2
  7. Rodriguez, José Antonio 3
  8. Zabaleta, Aintzane 4
  9. Paiva, Bruno 4
  10. Pastrana, Juan Carlos 1
  11. Páramo, José A. 1
  1. 1 Clínica Universitaria de Navarra
    info
    Clínica Universitaria de Navarra

    Pamplona, España

    ROR https://ror.org/03phm3r45

    Geographic location of the organization Clínica Universitaria de Navarra
  2. 2 Medicina Interna, Complejo Hospitalario de Navarra, Pamplona, España
  3. 3 Laboratorio de Aterotrombosis, CIMA-Universidad de Navarra, Pamplona, España
  4. 4 Laboratorio de Citometría de Flujo, CIMA-Universidad de Navarra, Pamplona, España
Show affiliations +
Journal:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168,  1578-1879

Year of publication: 2019

Volume: 31

Issue: 4

Pages: 152-159

Type: Article

DOI: 10.1016/J.ARTERI.2019.02.003 DIALNET GOOGLE SCHOLAR

More publications in: Clínica e investigación en arteriosclerosis

Abstract

Introduction Monocytes play an important role in atherosclerotic progression having both pro and anti-inflammatory effects depending on different circulating monocyte subpopulations. The objective of this study is to characterize these subpopulations and their association with cardiovascular risk factors. Methods Transversal study including 102 selected patients, mean age: 65 years-old (range 41-86), 69% males. A set of specific antibodies against classical monocytes (Mon1, CD14+CD16− CD300e+HLADR+), intermediate (Mon2, CD14+CD16+CD300e+HLADR+) and non-classical (Mon3, CD14−CD16+CD300e+HLADR+) was assayed. Three groups of patients were included: 17 asymptomatic with more than one cardiovascular risk factor (group 1), 56 subjects asymptomatic but with vascular pathology assessed by ultrasound or microalbuminuria (group 2) and 19 patients with a previous atherothrombotic event (group 3). The cardiovascular risk was determined by Framingham and REGICOR scores. Results An association between study groups and the percentage of Mon1 and Mon2 was observed (ANOVA, p < .05), being independent of age and sex for Mon2. Likewise Mon1 and Mon2 subpopulations were associated with cardiovascular adverse events (β = 0.86, p = .02 y β = 0.1 p = .002, respectively), independently of age and sex in the case of Mon2. Moreover the percentage of Mon3 was associated with the presence of several cardiovascular risk factors (β = 0.21, p = .04) in the univariate analysis. In addition, there was a correlation between the levels of Mon1 and Mon2 and leukocytes (r = 0.7, p < .001 and r = 0.26, p = .01, respectively). Conclusions The analysis of monocyte subpopulations may be clinically useful to stratify the inflammatory profile related to the different cardiovascular risk groups.

Data source: Dialnet